We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
SERUM RESISTIN IS ASSOCIATED WITH INFLAMMATION IN HIV-INFECTED PATIENTS UNDERGOING ANTIRETROVIRAL THERAPY.
- Authors
Tilişcan, Cătălin; Aramă, Victoria; Mihăilescu, Raluca; Munteanu, Daniela; Streinu-Cercel, Adrian; Ruta, Simona; Popescu, Cristina; Catana, Remulus; Lobodan, Alina; Sorin Aramă, Ştefan
- Abstract
Background. Conflicting reports are suggesting that resistin may be linked to the development of insulin resistance, dyslipidemia or inflammation in treated HIV-infected patients. Our objective was to evaluate the correlations between serum levels of resistin and glucose/lipid metabolism parameters and the presence of subclinical inflammation. Materials and Methods. Consecutive non-diabetic asymptomatic persons with confirmed HIV infection, undergoing stable antiretroviral therapy (ART) for at least six months, were included in the study. Blood samples were collected and tested for immunological and virological parameters, resistin, fasting triglycerides, total cholesterol, LDLcholesterol, HDL-cholesterol, fasting insulin, fasting plasma glucose. The Quantitative Insulin Sensitivity Check Index (QUICKI) was used to evaluate resistance to insulin. Results. We enrolled 89 HIV-infected persons undergoing ART, with a mean age of 32.1 years (range: 18-65). The median value of resistin was 5.5 (IQR=3.4) ng/mL. Resistin was not associated with BMI (p=0.08), the number of helper T cells (p=0.71) or the persistence of HIV replication (p=0.32). Resistin did not influence the serum levels of triglycerides (p=0.16), HDL-cholesterol (p=0.24), LDL-cholesterol (p=0.33), but was associated with an increase in total cholesterol (p=0.05). No statistical significant association between resistin and QUICKI (p=0.52) was found. CRP concentrations were significantly associated with resistin (R=0.231, p=0.03). Conclusions. Contrary to some of the previous reports, our data suggest that is unlikely that resistin is involved in the pathogenesis of insulin resistance or dyslipidemia in patients with HIV infection undergoing ART. Resistin seems to be associated with chronic subclinical inflammation, which is a major source of significant comorbidities for these patients.
- Subjects
INSULIN resistance; DYSLIPIDEMIA; HIV-positive persons; RESISTIN; LIPID metabolism; HIV infections; HIGHLY active antiretroviral therapy; TRIGLYCERIDES
- Publication
Internal Medicine / Medicină Internă, 2015, Vol 12, Issue 5, p23
- ISSN
1220-5818
- Publication type
Article